US equities |
SPCX $174.84 ▲+2.19% NVDA $242.09 ▲+1.33% MU $1,061.61 ▼-0.22% MRVL $291.47 ▲+7.45% AMD $647.89 ▲+2.55% SNDK $1,669.10 ▼-2.06% TSLA $381.17 ▲+0.64% AVGO $375.69 ▲+3.64%
FinancialContent

Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

41.62 -3.85 (-8.47%)
Delayed Quote Updated: 10:27 AM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Enliven Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130% ↗
This Boulder biotech advancing cancer drugs saw a notable insider sale amid strong 1-year stock gains and early clinical progress. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally ↗
Focused on cancer therapies, this Boulder-based biotech reported significant insider selling amid a year of sharp share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Medical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN? ↗
This clinical-stage biotech advancing cancer therapies reported a notable insider sale as its lead candidates progress in early trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors. ↗
This oncology-focused biotech, advancing kinase inhibitors for cancer, reported a notable insider sale amid strong one-year stock gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter ↗
This clinical-stage biotech develops precision genetic medicines for neurological and hepatic disorders via its PRISM platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million ↗
This Boulder-based biotech, developing targeted cancer therapies, reported a notable insider sale as Phase 1 trials advance for key drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k ↗
The Chief Scientific Officer of this biopharmaceutical company sold 20,000 shares in mid-January 2026, amid the company's stock rising 71% throughout the month. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
Issued on behalf of Oncolytics Biotech Inc. 
From Equity Insider
Via GlobeNewswire
S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours ↗
Via Stocktwits
Topics Government Stocks
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗
The company reported positive initial data from its ongoing Phase 1b clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia. 
Via Stocktwits
These stocks are gapping in today's session ↗
Via Chartmill
News headline image
Resemble AI Unleashes Chatterbox Turbo: A New Era for Open-Source Real-Time Voice AI
The artificial intelligence landscape, as of December 15, 2025, has been significantly reshaped by the release of Chatterbox Turbo, an advanced open-source text-to-speech (TTS) model developed by... 
Via TokenRing AI
Topics Artificial Intelligence Fraud Hacking
News headline image
With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
What's going on in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Friday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Enliven Posts Loss Beat and Cash Surge ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗
Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:ABBV),(NASDAQ:BGNE),(NASDAQ:HCM),(NASDAQ:ELVN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
News headline image
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
< Previous 1 2 Next >